Education
About Us
Working with TipRanks
Follow Us
Kymera Therapeutics (KYMR)
NASDAQ:KYMR
Top Page
Kymera Therapeutics
(NASDAQ:KYMR)
Rating:54Neutral
Price Target:
$30.00
▼( -0.43% Downside)
Positive Factors
Financial Health
Cash runway is updated to into 1H28 vs. mid-2027 previously, which extends runway past the KT-621 Ph 2b readouts.
Product Pipeline
KT-621 is a first-in-class STAT6 degrader that aims to achieve efficacy similar to existing successful treatments, potentially capturing a significant market share.
Strategic Partnerships
Kymera's partnership with Sanofi for KT-474 includes profit-sharing and milestone opportunities, enhancing the company's financial prospects.
Negative Factors
Competitive Landscape
Investors will likely welcome the discontinuation of the TYK2 program and associated burn given perceived crowding in the TYK2 landscape.
Program Discontinuation
The company made a strategic decision to discontinue development of oral TYK2 degrader, which is apt considering the competitive landscape and extending capital runway.
Kymera Therapeutics (KYMR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.05B
Dividend YieldN/A
Average Volume (3M)737.05K
Price to Earnings (P/E)―
Beta (1Y)2.48
Revenue Growth-25.85%
EPS Growth-23.89%
CountryUS
Employees208
SectorHealthcare
Sector Strength44
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.82
Shares Outstanding65,119,570
10 Day Avg. Volume533,700
30 Day Avg. Volume737,047
Financial Highlights & Ratios
PEG Ratio0.40
Price to Book (P/B)2.88
Price to Sales (P/S)0.00
P/FCF Ratio-9.42
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue6.35
Enterprise Value/Gross Profit48.37
Enterprise Value/Ebitda-2.82
Forecast
1Y Price Target
$54.00Price Target Upside79.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
Kymera Therapeutics Business Overview & Revenue Model
Company DescriptionKymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
How the Company Makes MoneyKymera Therapeutics generates revenue primarily through strategic collaborations and partnerships with other pharmaceutical and biotechnology companies. These partnerships often involve upfront payments, milestone payments, and potential royalties on sales of products developed using their technology. Additionally, the company may also receive funding through research grants and government contracts to support the development of their therapeutic candidates. As Kymera advances its own pipeline of drug candidates, the commercialization of approved therapies would also become a significant source of revenue.
Kymera Therapeutics Financial Statement Overview
Summary
Kymera Therapeutics demonstrates typical characteristics of a biotech firm in a growth phase with declining revenue and high R&D costs leading to net losses. Despite a strong equity base and low leverage, the company faces cash flow management challenges.Income Statement
Kymera Therapeutics has experienced declining revenue over the past year, with a notable drop of 40.1% from $78.59M to $47.07M. The company operates at a loss, as indicated by negative EBIT and net income, leading to negative margins. The gross profit margin remains high due to the absence of cost of goods sold, but the net profit margin is significantly negative, reflecting the company's high operating costs relative to its revenue.45
Neutral
Balance Sheet
The balance sheet shows strong equity relative to liabilities, with a debt-to-equity ratio of 0.10, indicating low leverage. However, the company's return on equity is negative due to its net losses. The equity ratio is healthy at 85.4%, suggesting stability in its asset financing structure, primarily through equity rather than debt.65
Positive
Cash Flow
Operating cash flow is negative, reflecting cash outflow from operations. However, the company has managed free cash flow deficit through substantial financing activities. There is a significant increase in free cash flow deficit from the previous period, indicating potential cash management challenges.50
Neutral
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 47.07M | 78.59M | 46.83M | 72.83M | 34.03M | Gross Profit |
| 39.70M | -110.49M | 43.85M | 70.44M | -28.07M | EBIT |
| -261.63M | -165.53M | -161.26M | -100.53M | -46.30M | EBITDA |
| -216.24M | -143.20M | -151.66M | -97.64M | -43.72M | Net Income Common Stockholders |
| -223.86M | -146.96M | -151.83M | -98.00M | -43.95M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 488.74M | 374.88M | 559.49M | 567.61M | 458.73M | Total Assets |
| 978.03M | 575.76M | 603.13M | 605.90M | 487.18M | Total Debt |
| 87.76M | 84.67M | 17.34M | 17.96M | 17.99M | Net Debt |
| -32.49M | -25.29M | -51.06M | -30.01M | -13.01M | Total Liabilities |
| 142.42M | 180.79M | 112.98M | 146.27M | 203.29M | Stockholders Equity |
| 835.62M | 394.97M | 490.15M | 459.64M | 283.89M |
| Cash Flow | Free Cash Flow | |||
| -207.34M | -137.31M | -155.92M | -130.54M | 79.03M | Operating Cash Flow |
| -194.50M | -102.83M | -153.09M | -128.95M | 88.13M | Investing Cash Flow |
| -404.08M | 139.89M | 20.52M | -99.83M | -422.59M | Financing Cash Flow |
| 608.85M | 4.19M | 153.00M | 250.28M | 289.26M |
Kymera Therapeutics Technical Analysis
Negative
30.13
Price Trends
29.78
Positive
33.84
Negative
39.82
Negative
Market Momentum
0.19
Positive
48.82
Neutral
38.35
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KYMR, the sentiment is Negative. The current price of 30.13 is below the 20-day moving average (MA) of 31.77, above the 50-day MA of 29.78, and below the 200-day MA of 39.82, indicating a neutral trend. The MACD of 0.19 indicates Positive momentum. The RSI at 48.82 is Neutral, neither overbought nor oversold. The STOCH value of 38.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KYMR.
Kymera Therapeutics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $2.06B | 13.58 | 24.71% | ― | 20.62% | 14.08% | |
66 Neutral | $2.16B | ― | 18.68% | ― | 41.67% | 75.79% | |
54 Neutral | $2.05B | ― | -32.17% | ― | -25.85% | -23.89% | |
54 Neutral | $1.75B | 2.67 | 60.26% | ― | 25.96% | ― | |
53 Neutral | $5.24B | 3.07 | -43.58% | 2.80% | 16.87% | -0.11% | |
45 Neutral | $1.78B | ― | -38.04% | ― | -82.38% | -164.76% | |
43 Neutral | $1.73B | ― | -23.34% | ― | ― | -14.19% |
* Healthcare Sector Average
Performance Comparison
KYMR
Kymera Therapeutics
30.17
-4.07
-11.89%
BCRX
BioCryst
10.07
3.74
59.08%
AGIO
Agios Pharma
30.11
-2.58
-7.89%
BEAM
Beam Therapeutics
17.22
-6.79
-28.28%
IRON
Disc Medicine
48.89
15.54
46.60%
HRMY
Harmony Biosciences Holdings
34.50
5.15
17.55%
Kymera Therapeutics Earnings Call Summary
Earnings Call Date:May 09, 2025
(Q1-2025)
| % Change Since: -2.08%|
Next Earnings Date:Aug 01, 2025
Earnings Call Sentiment Positive
Despite market challenges and strategic pausing of the TIC2 program, Kymera Therapeutics, Inc. demonstrated strong financial health and significant advancements in their pipeline, highlighted by the launch of new programs and promising preclinical results.Q1-2025 Updates
Positive Updates
Strong Financial Position
Kymera Therapeutics, Inc. reported having $775 million in cash reserves, extending their runway into the first half of 2028.
Promising Pipeline Advancements
The company has progressed five new molecules into the clinic since 2020, with plans to deliver 10 molecules by 2026. Notably, they achieved more than 90% degradation in preclinical studies across programs with the desired efficacy and safety profile.
Launch of IRAF5 Program
Kymera Therapeutics, Inc. introduced KT579, their first-in-class IRAF5 degrader, which has shown promising preclinical results in autoimmune diseases like lupus and RA.
STAT6 Degrader Progress
The company is advancing KT621, their oral STAT6 degrader, demonstrating potential to provide dupilumab-like efficacy with the convenience of an oral drug.
Preclinical Milestone Achievement
Kymera achieved a preclinical milestone in the IRAK4 program resulting in a $20 million payment expected in Q2 2025.
Negative Updates
Strategic Pause in TIC2 Program
Kymera Therapeutics, Inc. made a strategic decision not to advance their TIC2 degrader KT295 into clinical development due to resource allocation priorities and competitive landscape challenges.
Market Volatility and Resource Allocation
The company cited the need for prudent resource allocation amidst a volatile market environment, leading to strategic shifts in program focus.
Company Guidance
During the call, Kymera Therapeutics, Inc. provided guidance on their strategic focus and upcoming milestones. They reported $775 million in cash as of the end of the first quarter of 2025, extending their financial runway into the first half of 2028. The company has introduced IRAF5 as its latest high-value immunology program, alongside their existing STAT6 and IRAK4 programs. They announced that five new molecules have been brought into the clinic since 2020, with a goal to have ten by 2026. Over 300 subjects have been dosed across their pipeline, achieving more than 90% protein degradation in trials. The call also announced a strategic decision not to advance the TIC2 degrader into clinical development, reallocating resources to focus on STAT6 and IRAF5, aiming for clinical data readouts for STAT6 in June and the fourth quarter of 2025. The company expects to start a Phase 1 trial for IRAF5 in early 2026, with ongoing efforts to demonstrate best-in-class efficacy and safety profiles across their programs.Kymera Therapeutics Corporate Events
Product-Related AnnouncementsBusiness Operations and Strategy
Kymera Therapeutics Introduces KT-579 Targeting IRF5
Positive
May 9, 2025
On May 9, 2025, Kymera Therapeutics announced the introduction of KT-579, an oral degrader targeting IRF5, with potential applications in rheumatic and autoimmune diseases, expected to enter Phase 1 trials in early 2026. The company also reported progress in its KT-621 and KT-474 programs, including a $20 million milestone payment from Sanofi for the IRAK4 collaboration, and a strategic decision to focus resources on the STAT6 and IRF5 programs, extending its financial runway into 2028.
Executive/Board Changes
Kymera Therapeutics Grants Performance Stock Units to Executives
Neutral
Mar 3, 2025
On March 3, 2025, Kymera Therapeutics’ Board and Compensation Committee approved the grant of performance stock units (PSUs) to key employees, including executives, under the company’s 2020 Stock Option and Incentive Plan. These PSUs will vest in three installments based on achieving specific clinical milestones, potentially impacting employee incentives and aligning them with the company’s clinical development goals.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.